Pancreatic Cancer Research

ResearcherKyoto UniversityActive in the last 2 years

Michio Yoshimura

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-6665-2245; OpenAlex author ID A5025696595. Sources: OpenAlex.

Their work

Papers
21 (first author 3, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
38
Papers, trials and grants by year

2014: 1 paper · 2015: none · 2016: none · 2017: none · 2018: 2 papers · 2019: 1 paper · 2020: 3 papers · 2021: 1 paper · 2022: 1 paper · 2023: 6 papers · 2024: 1 paper · 2025: 5 papers

Papers 21

  1. Multi-Institutional Phase II Study on the Efficacy and Safety of Dynamic Tumor-Tracking, Moderately Hypofractionated Intensity-Modulated Radiotherapy in Patien… Co-author DOI 10.1002/cam4.70648↗
  2. Neoadjuvant chemoradiotherapy using moderately hypofractionated intensity-modulated radiotherapy for borderline resectable pancreatic cancer : Outcomes and pro… First author DOI 10.1007/s00066-025-02433-9↗
  3. Dosimetric performance of cone beam CT-guided adaptive carbon-ion radiotherapy with daily replanning for pancreatic cancer. Co-author DOI 10.1016/j.ejmp.2025.104991↗
  4. Proposing oligo-recurrence criteria in pancreatic ductal adenocarcinoma: A stratified analysis of locoregional treatment benefits. Co-author DOI 10.1016/j.pan.2025.04.012↗
  5. Neoadjuvant Chemoradiotherapy Using Moderately Hypofractionated Intensity-Modulated Radiotherapy Versus Upfront Surgery for Resectable Pancreatic Cancer: A Ret… Co-author DOI 10.1245/s10434-025-16956-z↗
  6. Protocol digest of a randomized phase III trial comparing S-1-based chemoradiotherapy with/without nivolumab for unresectable locally advanced or borderline re… Co-author DOI 10.1093/jjco/hyae084↗
  7. Potential utility of cone-beam CT-guided adaptive radiotherapy under end-exhalation breath-hold conditions for pancreatic cancer. Co-author DOI 10.1002/acm2.13827↗
  8. Safety and efficacy of neoadjuvant chemoradiotherapy with moderately hypofractionated intensity-modulated radiotherapy for resectable pancreatic cancer: A pros… Co-author DOI 10.1002/cam4.6470↗
  9. Association between homologous recombination gene variants and efficacy of oxaliplatin-based chemotherapy in advanced pancreatic cancer: prospective multicente… Co-author DOI 10.1007/s12032-023-02011-y↗
  10. Assessing target localization accuracy across different soft-tissue matching protocols using end-exhalation breath-hold cone-beam computed tomography in patien… Co-author DOI 10.1093/jrr/rrad048↗
  11. Impact of planning organ at risk volume margins and matching method on late gastrointestinal toxicity in moderately hypofractionated IMRT for locally advanced … First author DOI 10.1186/s13014-023-02288-3↗
  12. Correction: Impact of planning organ at risk volume margins and matching method on late gastrointestinal toxicity in moderately hypofractionated IMRT for local… First author DOI 10.1186/s13014-023-02321-5↗
  13. Impact of neoadjuvant intensity-modulated radiation therapy on borderline resectable pancreatic cancer with arterial abutment; a prospective, open-label, phase… Co-author DOI 10.1186/s12885-022-09244-6↗
  14. Statistical shape model-based planning organ-at-risk volume: application to pancreatic cancer patients. Co-author DOI 10.1088/1361-6560/abcd1b↗
  15. Impact of interfractional anatomical variation and setup correction methods on interfractional dose variation in IMPT and VMAT plans for pancreatic cancer pati… Co-author DOI 10.1002/acm2.12883↗
  16. Postoperative pancreatic fistulas decrease the survival of pancreatic cancer patients treated with surgery after neoadjuvant chemoradiotherapy: A retrospective… Co-author DOI 10.1016/j.suronc.2020.10.010↗
  17. Positional repeatability and variation in internal and external markers during volumetric-modulated arc therapy under end-exhalation breath-hold conditions for… Co-author DOI 10.1093/jrr/rraa054↗
  18. Accumulation of the delivered treatment dose in volumetric modulated arc therapy with breath-hold for pancreatic cancer patients based on daily cone beam compu… Co-author DOI 10.1002/mp.13566↗
  19. Evaluation of Dynamic Tumor-tracking Intensity-modulated Radiotherapy for Locally Advanced Pancreatic Cancer. Co-author DOI 10.1038/s41598-018-35402-7↗
  20. HIF-1 maintains a functional relationship between pancreatic cancer cells and stromal fibroblasts by upregulating expression and secretion of Sonic hedgehog. Co-author DOI 10.18632/oncotarget.24156↗
  21. Radiotherapy for patients with isolated local recurrence of primary resected pancreatic cancer. Prolonged disease-free interval associated with favorable progn… Co-author DOI 10.1007/s00066-014-0610-8↗

Closest collaborators

The 25 strongest of 38 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Takashi Mizowaki · 16 shared papers, 2014–2025 · strength 2.62
  2. Mitsuhiro Nakamura · 11 shared papers, 2018–2025 · strength 1.99
  3. Ryo Ashida · 8 shared papers, 2019–2025 · strength 1.38
  4. Takahiro Iwai · 6 shared papers, 2023–2025 · strength 1.30
  5. Kazuyuki Nagai · 6 shared papers, 2020–2025 · strength 1.00
  6. Toshihiko Masui · 6 shared papers, 2020–2025 · strength 0.94
  7. Etsuro Hatano · 5 shared papers, 2022–2025 · strength 0.89
  8. Akihisa Fukuda · 5 shared papers, 2022–2025 · strength 0.89
  9. Ayaka Ogawa · 4 shared papers, 2023–2025 · strength 0.86
  10. Masashi Kanai · 5 shared papers, 2022–2025 · strength 0.83
  11. Kei Yamane · 3 shared papers, 2025 · strength 0.62
  12. Junichi Matsubara · 3 shared papers, 2023–2025 · strength 0.55
  13. Masahiro Hiraoka · 4 shared papers, 2014–2025 · strength 0.45
  14. Shinji Üemoto · 4 shared papers, 2014–2023 · strength 0.42
  15. Makoto Sasaki · 2 shared papers, 2020–2023 · strength 0.34
  16. Asahi Sato · 2 shared papers, 2022–2025 · strength 0.32
  17. Lukas Fabrizio Klassen · 1 shared paper, 2025 · strength 0.27
  18. Kyoichi Takaori · 3 shared papers, 2014–2022 · strength 0.27
  19. Katsuyuki Karasawa · 1 shared paper, 2025 · strength 0.25
  20. Yuichiro Uchida · 2 shared papers, 2020–2022 · strength 0.23
  21. Yusuke Sano · 1 shared paper, 2024 · strength 0.21
  22. Masato Ozaka · 1 shared paper, 2024 · strength 0.21
  23. Junji Furuse · 1 shared paper, 2024 · strength 0.21
  24. Makoto Ueno · 1 shared paper, 2024 · strength 0.21
  25. Chigusa Morizane · 1 shared paper, 2024 · strength 0.21

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.